Leqembi's Inclusion in China's Innovative Drug List
BioArctic AB's partner, Eisai, has announced a significant achievement as Leqembi (lecanemab) is now part of China's "Commercial Insurance Innovative Drug List.” This notable addition, made by the National Healthcare Security Administration (NHSA), is poised to improve access to treatment for early Alzheimer's Disease (AD) in China.
Understanding the Commercial Insurance Innovative Drug List
The establishment of the Commercial Insurance Innovative Drug List reflects new Chinese government policies aimed at supporting the progress and accessibility of innovative medications. Its primary goal is to bridge the gap in coverage between the national reimbursement system and innovative treatments that fill crucial unmet medical needs. This new list will prompt a dialogue between commercial insurance companies and pharmaceutical firms to finalize coverage specifics and create tailored insurance products for the specified medications. Importantly, the list is set to come into force on January 1, 2026.
Statistics on Alzheimer’s Disease in China
According to Eisai's estimates, there were approximately 17 million individuals suffering from mild cognitive impairment or mild dementia due to Alzheimer's disease in China as of 2024. This number is anticipated to grow as the population continues to age, thereby increasing the demand for effective treatments.
Leqembi's Journey and Collaboration Details
Eisai first launched Leqembi in China in June 2024, distributing the drug within the private market. The development of Leqembi stems from a long-term partnership between BioArctic and Eisai. The antibody itself originates from the foundational research of Professor Lars Lannfelt and the pioneering Arctic mutation discovery in the realm of Alzheimer's disease.
Regulatory Approvals and Studies
The approval of Leqembi spans across 51 countries, with an additional 9 countries currently undergoing regulatory review. The treatment has been designed to be administered bi-weekly for the first 18 months, followed by a maintenance dose every four weeks, a regimen recognized in numerous countries including the United Kingdom, China, and the U.S. Recently, the U.S. FDA has broadened access to Leqembi Iqlik™ for subcutaneous administration during maintenance therapy for early Alzheimer's patients.
Ongoing Clinical Trials and Future Directions
As of July 2020, Eisai's Phase 3 clinical study, AHEAD 3-45, is still underway. This study focuses on individuals showing preclinical signs of Alzheimer's disease, ensuring rigorous testing and validation of lecanemab's efficacy. Recruitment for AHEAD 3-45 was completed by October 2024, marking another significant step in clinical progression. In parallel, the Tau NexGen clinical study for Dominantly Inherited AD is also currently facilitating trials involving lecanemab as a core therapy.
Long-term Collaboration Between BioArctic and Eisai
Since 2005, BioArctic has been in a comprehensive collaboration with Eisai dedicated to creating and marketing therapeutics for Alzheimer's disease. Key agreements, including the Development and Commercialization agreement for the lecanemab antibody initiated in 2007, lay the groundwork for this fruitful partnership. Eisai oversees clinical developments and market approval pursuits globally, while BioArctic maintains rights for lecanemab's commercialization specifically in the Nordic regions, aiming for a future joint introduction with Eisai.
About BioArctic AB and Its Mission
BioArctic AB is a Swedish biopharmaceutical firm focused on pioneering treatments that can alter the course of neurodegenerative diseases. This organization developed Leqembi, distinguished as the first drug globally proven to impede the progression of early Alzheimer's disease while improving cognitive function. Furthermore, BioArctic's research portfolio extends to alternative treatments, including antibodies for Parkinson's disease and ALS, leveraging innovative technologies like the BrainTransporter™ aimed at improving therapeutic efficacy by enabling efficient delivery across the blood-brain barrier.
Frequently Asked Questions
What is Leqembi, and how does it work?
Leqembi (lecanemab) is an antibody treatment aimed at Alzheimer's disease, targeting amyloid-beta proteins to slow disease progression.
Why is the Commercial Insurance Innovative Drug List important?
This list is crucial in improving access to innovative treatments by allowing commercial insurance companies to provide coverage for significant new drugs.
When will the Commercial Insurance Innovative Drug List take effect?
The list is scheduled to be implemented on January 1, 2026.
How many countries have approved Leqembi?
Leqembi is currently approved in 51 countries worldwide.
What is the ongoing clinical development for Leqembi?
The ongoing clinical studies, including AHEAD 3-45, are focused on assessing the treatment's efficacy in patients with preclinical Alzheimer's symptoms.
